Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin February 28, 2022 Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress Read More »
Plexium Announces $102M Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform Portfolio News / By Karina Tin February 23, 2022 Plexium Announces $102M Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform Read More »
Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth Portfolio News / By Karina Tin February 17, 2022 Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth Read More »
Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs Portfolio News / By Karina Tin February 15, 2022 Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs Read More »
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Portfolio News / By Karina Tin February 7, 2022 NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Read More »
Plexium and Amgen Announce Multi-year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies Portfolio News / By Karina Tin February 3, 2022 Plexium and Amgen Announce Multi-year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies Read More »
Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors Portfolio News / By Karina Tin February 3, 2022 Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors Read More »
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin January 27, 2022 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update Read More »
ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications Portfolio News / By Karina Tin January 25, 2022 ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications Read More »
eFFECTOR Therapeutics Provides Pipeline and Business Updates Portfolio News / By Karina Tin January 24, 2022 eFFECTOR Therapeutics Provides Pipeline and Business Updates Read More »
